Increasing pharmacological knowledge about human neurological and psychiatric disorders through functional neuroimaging and its application in drug discovery

Current Opinion in Pharmacology

Volumn 14, Issue 1, 2014, Pages 54-61

  Nathan, Pradeep J ^a,b,c   Phan, K Luan ^d,e   Harmer, Catherine J ^f   Mehta, Mitul A ^g   Bullmore, Edward T ^a,h  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MONASH UNIVERSITY   (Australia)

^c UCB PHARMA   (Belgium)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e JESSE BROWN VA MEDICAL CENTER   (United States)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; APREPITANT; BENZODIAZEPINE DERIVATIVE; GSK 1521498; KETAMINE; MU OPIATE RECEPTOR ANTAGONIST; NALMEFENE; NALTREXONE; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; UNCLASSIFIED DRUG;

ALCOHOLISM; ANXIETY DISORDER; ARTICLE; BOLD SIGNAL; BRAIN REGION; COGNITION; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MENTAL DISEASE; NEUROIMAGING; NEUROLOGIC DISEASE; OVERNUTRITION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELIABILITY; SCHIZOPHRENIA; TREATMENT DURATION; VALIDITY;

ANIMALS; BIOLOGICAL MARKERS; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DESIGN; DRUG DISCOVERY; FUNCTIONAL NEUROIMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MENTAL DISORDERS;

EID: 84890065909     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.11.009     Document Type: Review

References (64)

1. S. Ogawa, D.W. Tank, R. Menon, J.M. Ellermann, S.G. Kim, H. Merkle, and Ugurbil Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging Proc Natl Acad Sci USA 89 1992 5951 5955
2. J.F. Cryan, and F.F. Sweeney The age of anxiety: role of animal models of anxiolytic action in drug discovery Br J Pharmacol 164 2011 1129 1161
3. M.J. Millan The neurobiology and control of anxious states Prog Neurobiol 70 2003 83 244 (Pubitemid 37309295)
4. E.I. Martin, K.J. Ressler, E. Binder, and C.B. Nemeroff The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology Clin Lab Med 30 2010 865 891
5. M.P. Paulus, and M.B. Stein Role of functional magnetic resonance imaging in drug discovery Neuropsychol Rev 17 2007 179 188 (Pubitemid 46889565)
6. P. Baldinger, G.S. Kranz, D. Haeusler, M. Savli, M. Spies, C. Philippe, A. Hahn, A. Höflich, W. Wadsak, M. Mitterhauser, R. Lanzenberger, and S. Kasper Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET Neuroimage 2013 pii: S1053-8119(13)01011-2
7. 11C]DASB positron emission tomography study Am J Psychiatry 161 2004 826 835 (Pubitemid 38625335)
8. D.F. Wong, J. Tauscher, and G. Gründer The role of imaging in proof of concept for CNS drug discovery and development Neuropsychopharmacology 34 2009 187 203
9. D. Borsook, L. Becerra, and R. Hargreaves A role for fMRI in optimizing CNS drug development Nat Rev Drug Discov 5 2006 411 424
10. J.P. Hamilton, A. Etkin, D.J. Furman, M.G. Lemus, R.F. Johnson, and I.H. Gotlib Functional neuroimaging of major depressive disorder: a meta-analysis and new integration of base line activation and neural response data Am J Psychiatry 169 2012 693 703
11. A. Etkin, and T.D. Wager Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia Am J Psychiatry 164 2007 1476 1488 (Pubitemid 350069724)
12. P. Delaveau, M. Jabourian, C. Lemogne, S. Guionnet, L. Bergouignan, and P. Fossati Brain effects of antidepressants in major depression: a meta-analysis of emotional processing studies J Affect Disord 130 2011 66 74
13. C.H. Fu, H. Steiner, and S.G. Costafreda Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies Neurobiol Dis 52 2013 75 83
14. K.L. Phan, E.F. Coccaro, M. Angstadt, K.J. Kreger, H.S. Mayberg, I. Liberzon, and M.B. Stein Corticolimbic brain reactivity to social signals of threat before and after sertraline treatment in generalized social phobia Biol Psychiatry 73 2013 329 336
15. T. Furmark, M. Tillfors, I. Marteinsdottir, H. Fischer, A. Pissiota, B. Långström, and M. Fredrikson Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy Arch Gen Psychiatry 59 2002 425 433 (Pubitemid 34477677)
16. C.J. Harmer, C.E. Mackay, C.B. Reid, P.J. Cowen, and G.M. Goodwin Antidepressant drug treatment modifies the neural processing of nonconscious threat cues Biol Psychiatry 59 2006 816 820
17. E. Arce, A.N. Simmons, K.L. Lovero, M.B. Stein, and M.P. Paulus Escitalopram effects on insula and amygdala BOLD activation during emotional processing Psychopharmacology (Berl) 196 2008 661 672
18. A.N. Simmons, E. Arce, K.L. Lovero, M.B. Stein, and M.P. Paulus Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers Int J Neuropsychopharmacol 12 2009 1009 1020
19. M.P. Paulus, J.S. Feinstein, G. Castillo, A.N. Simmons, and M.B. Stein Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing Arch Gen Psychiatry 62 2005 282 288 (Pubitemid 40990973)
20. E.B. McClure, A. Adler, C.S. Monk, J. Cameron, S. Smith, E.E. Nelson, E. Leibenluft, M. Ernst, and D.S. Pine fMRI predictors of treatment outcome in pediatric anxiety disorders Psychopharmacology (Berl) 191 2007 97 105 (Pubitemid 46294944)
21. V. Faria, L. Appel, F. Åhs, C. Linnman, A. Pissiota, Ö. Frans, M. Bani, P. Bettica, E.M. Pich, E. Jacobsson, K. Wahlstedt, M. Fredrikson, and T. Furmark Amygdala subregions tied to SSRI and placebo response in patients with social anxiety disorder Neuropsychopharmacology 37 2012 2222 2232
22. J.B. Nitschke, I. Sarinopoulos, D.J. Oathes, T. Johnstone, P.J. Whalen, R.J. Davidson, and N.H. Kalin Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response Am J Psychiatry 166 2009 302 310
23. P.J. Whalen, T. Johnstone, L.H. Somerville, J.B. Nitschke, S. Polis, A.L. Alexander, R.J. Davidson, and N.H. Kalin A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder Biol Psychiatry 63 2008 858 863 (Pubitemid 351458450)
24. T. Schunck, A. Mathis, G. Erb, I.J. Namer, A. Demazières, and R. Luthringer Effects of lorazepam on brain activity pattern during an anxiety symptom provocation challenge J Psychopharmacol 24 2010 701 708
25. G. Leicht, C. Mulert, D. Eser, P.G. Sämann, M. Ertl, A. Laenger, S. Karch, O. Pogarell, T. Meindl, M. Czisch, and R. Rupprecht Benzodiazepines counteract rostral anterior cingulate cortex activation induced by cholecystokinin-tetrapeptide in humans Biol Psychiatry 73 2013 337 344
26. P. Kirsch, C. Esslinger, Q. Chen, D. Mier, S. Lis, S. Siddhanti, H. Gruppe, V.S. Mattay, B. Gallhofer, and A. Meyer-Lindenberg Oxytocin modulates neural circuitry for social cognition and fear in humans J Neurosci 25 2005 11489 11490
27. K.L. Phan, M. Angstadt, J. Golden, I. Onyewuenyi, A. Popovska, and H. de Wit Cannabinoid modulation of amygdala reactivity to social signals of threat in humans J Neurosci 28 2008 2313 2319 (Pubitemid 351348194)
28. R.L. Aupperle, D. Tankersley, L.N. Ravindran, T. Flagan, N.R. Stein, M.B. Stein, and M.P. Paulus Pregabalin effects on neural response to emotional faces Front Hum Neurosci 6 2012 42
29. D. Terburg, S. Syal, L.A. Rosenberger, S. Heany, N. Phillips, N. Gericke, D.J. Stein, and J. van Honk Acute effects of Sceletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus Neuropsychopharmacology 2013 10.1038/npp.2013.183
30. I. Labuschagne, K.L. Phan, A. Wood, M. Angstadt, P. Chua, M. Heinrichs, J.C. Stout, and P.J. Nathan Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder Neuropsychopharmacology 35 2010 2403 2413
31. C.J. Harmer, P.J. Cowen, and G.M. Goodwin Efficacy markers in depression J Psychopharmacol 25 2011 1148 1158
32. J.P. Roiser, and B.J. Sahakian Hot and cold cognition in depression CNS Spectrosc 18 2013 139 149
33. S.G. Disner, C.G. Beevers, E.A. Haigh, and A.T. Beck Neural mechanisms of the cognitive model of depression Nat Rev Neurosci 12 2011 467 477
34. R. Tranter, D. Bell, P. Gutting, C. Harmer, D. Healy, and I.M. Anderson The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients J Affect Disord 118 2009 87 93
35. C.J. Harmer, G.M. Goodwin, and P.J. Cowen Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action Br J Psychiatry 195 2009 102 108
36. A. Reinecke, L. Waldenmaier, M.J. Cooper, and C.J. Harmer Changes in automatic threat processing precede and predict clinical changes with exposure-based cognitive-behavior therapy for panic disorder Biol Psychiatry 73 2013 1064 1070
37. C. McCabe, P.J. Cowen, and C.J. Harmer NK1 receptor antagonism and the neural processing of emotional information in healthy volunteers Int J Neuropsychopharmacol 12 2009 1261 1274
38. P. Chandra, S. Hafizi, R.M. Massey-Chase, G.M. Goodwin, P.J. Cowen, and C.J. Harmer NK1 receptor antagonism and emotional processing in healthy volunteers J Psychopharmacol 24 2010 481 487
39. A. Pringle, S.F. McTavish, C. Williams, R. Smith, P.J. Cowen, and C.J. Harmer Short-term NK1 receptor antagonism and emotional processing in healthy volunteers Psychopharmacology (Berl) 215 2011 239 246
40. M.S. George, R.F. Anton, C. Bloomer, C. Teneback, D.J. Drobes, J.P. Lorberbaum, Z. Nahas, and D.J. Vincent Activation of prefrontal cortex and anterior thalamus in alcoholic subjects on exposure to alcohol-specific cues Arch Gen Psychiatry 58 2001 345 352 (Pubitemid 32299531)
41. H. Myrick, R.F. Anton, X. Li, S. Henderson, D. Drobes, K. Voronin, and M.S. George Differential brain activity in alcoholics and social drinkers to alcohol cues: relationship to craving Neuropsychopharmacology 29 2004 393 402 (Pubitemid 38175156)
42. J. Wrase, S.M. Grüsser, S. Klein, C. Diener, D. Hermann, H. Flor, K. Mann, D.F. Braus, and A. Heinz Development of alcohol-associated cues and cue-induced brain activation in alcoholics Eur Psychiatry 17 2002 287 291 (Pubitemid 35168007)
43. S.M. Grüsser, J. Wrase, S. Klein, D. Hermann, M.N. Smolka, M. Ruf, W. Weber-Fahr, H. Flor, K. Mann, D.F. Braus, and A. Heinz Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics Psychopharmacology (Berl) 175 2004 296 302 (Pubitemid 39361918)
44. H. Myrick, R.F. Anton, X. Li, S. Henderson, P.K. Randall, and K. Voronin Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people Arch Gen Psychiatry 65 2008 466 475 (Pubitemid 351519896)
45. S.E. Lukas, S.B. Lowen, K.P. Lindsey, N. Conn, W. Tartarini, J. Rodolico, G. Mallya, C. Palmer, and D.M. Penetar Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study Neuroimage 78 2013 176 185
46. W. Killgore Cortical and limbic activation during viewing of high- versus low-calorie foods NeuroImage 19 2003 1381 1394 (Pubitemid 37028317)
47. P.C. Fletcher, A. Napolitano, A. Skeggs, S.R. Miller, B. Delafont, V.C. Cambridge, S. de Wit, P.J. Nathan, A. Brooke, S. O'Rahilly, I.S. Farooqi, and E.T. Bullmore Distinct modulatory effects of satiety and sibutramine on brain responses to food images in humans: a double dissociation across hypothalamus, amygdala, and ventral striatum J. Neurosci 30 2010 14346 14350
48. Y. Rothemund, C. Preuschhof, G. Bohner, H.C. Bauknecht, R. Klingebiel, H. Flor, and B.F. Klapp Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese individuals NeuroImage 37 2007 410 421 (Pubitemid 47444263)
49. A. Schienle, A. Schäfer, A. Hermann, and D. Vaitl Binge-eating disorder: reward sensitivity and brain activation to images of food Biol Psychiatry 65 2009 654 661
50. L.K. Heisler, L.K. Heisler, E.E. Jobst, G.M. Sutton, L. Zhou, E. Borok, Z. Thornton-Jones, H.Y. Liu, J.M. Zigman, N. Balthasar, T. Kishi, C.E. Lee, C.J. Aschkenasi, C.Y. Zhang, J. Yu, O. Boss, K.G. Mountjoy, P.G. Clifton, B.B. Lowell, J.M. Friedman, T. Horvath, A.A. Butler, J.K. Elmquist, and M.A. Cowley Serotonin reciprocally regulates melanocortin neurons to modulate food intake Neuron 51 2006 239 249 (Pubitemid 44063615)
51. P.J. Nathan, B.V. O'Neill, M.A. Bush, A. Koch, W.X. Tao, K. Maltby, A. Napolitano, A.C. Brooke, A.L. Skeggs, C.S. Herman, A.L., Larkin, D.M. Ignar, D.B. Ricjards, P.M. Williams, and E.T. Bullmore Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety PK and PD investigation with GSK1521498 a novel mu-opioid receptor inverse agonist J Clin Pharmacol 52 2012 464 474
52. H. Ziauddeen, S.R. Chamberlain, P.J. Nathan, A. Koch, K. Maltby, M. Bush, W.X. Tao, A. Napolitano, A.L. Skeggs, A.C. Brooke, L. Cheke, N.S. Clayton, I. Sadaf Farooqi, S. O'Rahilly, D. Waterworth, K. Song, L. Hosking, D.B. Richards, P.C. Fletcher, and E.T. Bullmore Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects Mol Psychiatry 2012 10.1038/mp.2012.154 [Epub ahead of print]
53. E.A. Rabiner, J. Beaver, A. Makwana, G. Searle, C. Long, P.J. Nathan, R.D. Newbould, J. Howard, S.R. Miller, M.A. Bush, S. Hill, R. Reiley, J. Passchier, R.N. Gunn, P.M. Matthews, and E.T. Bullmore Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans Mol Psychiatry 16 2011 826 835
54. M.F. Green What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153 1996 321 330 (Pubitemid 26074706)
55. C.R. Bowie, A. Reichenberg, T.L. Patterson, R.K. Heaton, and P.D. Harvey Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms Am J Psychiatry 163 2006 418 425 (Pubitemid 44469383)
56. M.F. Green Schizophrenia from a Neurocognitive Perspective. Probing the Impenerable Darkness 1998 Allyn and Bacon Boston, MA
57. 1H-MRS: relationship to ketamine-induced psychopathology Molecular Psychiatry 17 2012 664 665
58. J.F. Deakin, J. Lees, S. McKie, J.E. Hallak, S.R. Williams, and S.M. Dursun Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study Arch Gen Psychiatry 65 2008 154 164 (Pubitemid 351214314)
59. S. De Simoni, A.J. Schwarz, O.G. O'Daly, A.F. Marquand, C. Brittain, C. Gonzales, S. Stephenson, S.C. Williams, and M.A. Mehta Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers Neuroimage 64 2013 75 90
60. C.L. Chin, J. Upadhyay, G.J. Marek, S.J. Baker, M. Zhang, M. Mezler, G.B. Fox, and M. Day Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals JPET 336 2011 709 715
61. A. Anticevic, M. Gancsos, J.D. Murray, G. Repovs, N.R. Driesen, D.J. Ennis, M.J. Niciu, P.T. Morgan, T.S. Surti, M.H. Bloch, R. Ramani, M.A. Smith, X.J. Wang, J.H. Krystal, and P.R. Corlett NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia Pro. Natl Acad Sci USA 109 2012 16720 16730
62. N.R. Driesen, G. McCarthy, Z. Bhagwagar, M. Bloch, V. Calhoun, D.C. D'Souza, R. Gueorguieva, G. He, R. Ramachandran, R.F. Suckow, A. Anticevic, P.T. Morgan, and J.H. Krystal Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans Molecular Psychiatry 18 2013 1199 1204
63. O.M. Doyle, S. De Simoni, A.J. Schwarz, C. Brittain, O.G. O'Daly, S.C. Williams, and M.A. Mehta Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents JPET 345 2013 151 160
64. O.M. Doyle, J. Ashburner, F.O. Zelaya, S.C. Williams, M.A. Mehta, and A.F. Marquand Multivariate decoding of brain images using ordinal regression Neuroimage 81 2013 347 357